Geoffrey Raymond OxnardMD
Dr. Geoffrey R. Oxnard is a thoracic oncologist with two primary areas of research. Through collaborations with molecular pathologists and laboratory researchers, he is interested in identifying subpopulations of lung cancer with unique clinical and molecular characteristics. For example, they have recently identified that lung cancer patients with T790M-mediated acquired resistance to erlotinib (Tarceva) have a favorable outcome, likely indicating a need for a unique therapeutic strategy.
Additionally, he perform research with colleagues in radiology and medical physics to explore better ways of analyzing response and progression in clinical trials and correlative research. In a recent analysis, they showed that volumetric CT measurement after only 3 weeks of gefitinib is able to accurately distinguish which lung cancers harbor sensitizing mutations. Multiple analyses of industry and cooperative group imaging data are ongoing through collaborations with Lawrence Schwartz, Chair of Radiology, Columbia University.